entertainment -WSS

entertainment

author：Wikipedia 2025-10-01 18:07:54 - browse：2

KalVista Pharmaceuticals said Tuesday that its oral, on-demand treatment for the swelling “attacks” commonly experienced by patients with a genetic condition called hereditary angioedema achieved the goals of a Phase 3 clinical trial.

Based on the study results, the company plans to submit a marketing application to the Food and Drug Administration by the middle of the year. Regulatory filings in Europe and Japan will be completed later in the year.

In the Phase 3 study involving 136 participants, a low and high dose of Kalvista’s drug, called sebetralstat, showed a median time to the beginning of symptom relief of 1.6 hours and 1.8 hours, respectively, compared to 6.7 hours for a placebo. The result was statistically significant and achieved the study’s main efficacy goal.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Prior authorization reform is both possible and imperative

WSS

Feed a cold, starve a fever? Here’s what science says

Dana Farber says 6 studies to be retracted and 31 corrected

FDA sets aggressive timeline for overhauling inspection procedures

Kansas bar where gunfire wounded 9 last month closes permanently

Paxlovid rebound happens. Why and to whom are still a mystery

Failure, not just success, should guide future doctors

hotspot

entertainment

explore

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

McConnell is warmly embraced by Kentucky Republicans amid questions about his health

Drug repurposing or repositioning? The language matters

Sweden knocks USA out of World Cup in penalty kicks

BioMarin wins approval for gene therapy to treat hemophilia A

Kansas bar where gunfire wounded 9 last month closes permanently

Psychedelics group wrestles with new pharma identity

Mexico finds 491 migrants being held at vacant lot, almost all are from Guatemala

Apple is now the first public company to be valued at $3 trillion

Mass General, Mayo Clinic look to monetize custom

focus

Microsoft launches AI tool for clinical documentation through Epic

Paxlovid rebound happens. Why and to whom are still a mystery

Cardiologists urge adding sexual orientation, gender identity to health records

McConnell is warmly embraced by Kentucky Republicans amid questions about his health

There's an unseen cost to disruptive road

Slovenia has suffered its worst

entertainment

leisure time

entertainment

Wikipedia